Wednesday, July 30, 2025 Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27Chapman J-AW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, Virk S, Goss PE, Ingle JN, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Tozer R, D’Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Gelmon KA, Whelan TJ, Elliott C, Shepherd LE, Chen BE, Taylor KJ. Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole. Breast Cancer Research and Treatment 213: 51-61. 2025.https://doi.org/10.1007/s10549-025-07749-9 Statistically standardized estrogen receptor and progesterone receptor differentiated prognosis. Researchers examined statistically standardized human epidermal growth receptor 2 (HER2). Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation StudyEl Kababji S, Mitsakakis N, Jonker E, Beltran-Bless A-A, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard M-F, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnant M, Clemons M, El Emam K. Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study. Journal of Medical Internet Research 27: e66821. 2025.https://www.jmir.org/2025/1/e66821 This study aimed to perform a comprehensive evaluation on the extent generative models can be used to simulate additional patients to compensate for insufficient accrual in clinical trials.
